GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Inventories, Raw Materials & Components

Pharos IBio Co (XKRX:388870) Inventories, Raw Materials & Components : ₩0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Inventories, Raw Materials & Components?

Pharos IBio Co's inventories, raw materials & components for the quarter that ended in Dec. 2024 was ₩0.00 Mil.


Pharos IBio Co Inventories, Raw Materials & Components Historical Data

The historical data trend for Pharos IBio Co's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Inventories, Raw Materials & Components Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

Pharos IBio Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharos IBio Co Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Pharos IBio Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines